EyePoint Pharmaceuticals, Inc. (EYPT)

8.94 -0.14 (-1.54%) At close: 4:00PM EDT

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street
Suite B300
Watertown, MA 02472
United States
617 926 5000
http://eyepointpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 98

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Nancy S. Lurker	Pres, CEO & Director	736.41k	N/A	1957
Mr. George O. Elston	CFO & Head of Corp. Devel.	489.15k	N/A	1965
Dr. Jay S. Duker	Chief Strategic Scientific Officer	53k	N/A	1959
Dr. Dario A. Paggiarino	Sr. VP & Chief Medical Officer	541.39k	N/A	1957
Mr. Said Saim	Chief Technology Officer	N/A	N/A	1958
Mr. Ron I. Honig Esq.	Sr. VP, Gen. Counsel & Company Sec.	N/A	N/A	N/A
Ms. Jennifer Leonard	Sr. VP of HR & IT	N/A	N/A	N/A
Dr. John Weet	Sr. VP of Regulatory	N/A	N/A	N/A
Mr. David Scott Jones	Sr. VP & Chief Commercial Officer	N/A	N/A	1967
Dr. Anna Kluczewska	CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Corporate Governance

EyePoint Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.